$9.47
0.42% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US2928121043
Symbol
ENFN

Enfusion Stock price

$9.47
+1.27 15.49% 1M
+0.24 2.60% 6M
-0.23 2.37% YTD
+0.60 6.76% 1Y
-10.34 52.20% 3Y
-10.34 52.20% 5Y
-10.34 52.20% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.04 0.42%
ISIN
US2928121043
Symbol
ENFN

Key metrics

Market capitalization $886.43m
Enterprise Value $895.09m
P/E (TTM) P/E ratio 322.37
EV/FCF (TTM) EV/FCF 55.84
EV/Sales (TTM) EV/Sales 4.75
P/S ratio (TTM) P/S ratio 4.71
P/B ratio (TTM) P/B ratio 13.63
Revenue growth (TTM) Revenue growth 15.30%
Revenue (TTM) Revenue $188.35m
EBIT (operating result TTM) EBIT $6.41m
Free Cash Flow (TTM) Free Cash Flow $16.03m
Cash position $34.45m
EPS (TTM) EPS $0.03
P/E forward 129.73
P/S forward 4.33
EV/Sales forward 4.37
Short interest 4.27%
Show more

Is Enfusion a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Enfusion Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Enfusion forecast:

4x Buy
40%
3x Hold
30%
3x Sell
30%

Analyst Opinions

10 Analysts have issued a Enfusion forecast:

Buy
40%
Hold
30%
Sell
30%

Financial data from Enfusion

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
188 188
15% 15%
100%
- Direct Costs 62 62
18% 18%
33%
126 126
14% 14%
67%
- Selling and Administrative Expenses 84 84
19% 19%
45%
- Research and Development Expense 24 24
35% 35%
13%
19 19
17% 17%
10%
- Depreciation and Amortization 12 12
12% 12%
6%
EBIT (Operating Income) EBIT 6.41 6.41
44% 44%
3%
Net Profit 3.75 3.75
33% 33%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Enfusion directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enfusion Stock News

Positive
Reuters
7 days ago
Enfusion , a U.S. software provider for asset managers, is in talks with investment bankers to evaluate its options that could include a potential sale, according to people familiar with the matter.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN .
Positive
Seeking Alpha
about one month ago
ENFN's Q2 2024 earnings show growth in revenue and margins, with potential for growth acceleration in the future. ENFN is successfully penetrating new markets and upmarket, despite challenges in the macro environment. The key to ENFN's positive rerating lies in reaccelerating growth and improving profitability.
More Enfusion News

Company Profile

Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded in 2006 and is headquartered in Chicago, IL.

Head office United States
CEO Oleg Movchan
Employees 1,102
Founded 2006
Website enfusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today